Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changli Wei

Showing results (31-40 of 79) with videos related to

Pageof 8
Sort By:
Transplantation|April 2, 2014
Podocyte foot process effacement in postreperfusion allograft biopsiesGeorge W Burke, Jei-Wen Chang, Victoriano Pardo, et al.
American Journal of Physiology. Renal Physiology|November 24, 2017
Podocytes exhibit a specialized protein quality control employing derlin-2 in kidney diseaseGuohui Ren, Nicholas J Tardi, Fumihiko Matsuda, et al.
Transplantation|April 14, 2012
Podocyte foot process effacement in postreperfusion allograft biopsies correlates with early recurrence of proteinuria in focal segmental glomerulosclerosisJei-Wen Chang, Victoriano Pardo, Junichiro Sageshima, et al.
Cardio-Oncology (London, England)|January 15, 2024
Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory studyJian Chu, Lillian Tung, Issam Atallah, et al.
Cardio-Oncology (London, England)|February 6, 2024
Correction: Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin‑treated breast cancer patients: a prospective exploratory studyJian Chu, Lillian Tung, Issam Atallah, et al.
Journal of the American Society of Nephrology : JASN|June 8, 2019
Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney DiseaseSalim S Hayek, Douglas P Landsittel, Changli Wei, et al.
Annals of the New York Academy of Sciences|August 14, 2018
Wnt signaling in bone, kidney, intestine, and adipose tissue and interorgan interaction in agingDi Chen, Rong Xie, Bing Shu, et al.
Kidney International Reports|January 10, 2022
Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte β3 IntegrinMichelle A Hladunewich, Dan Cattran, Sanjeev M Sethi, et al.
Transplantation|July 12, 2013
Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapyNada Alachkar, Changli Wei, Lois J Arend, et al.
Transplantation|September 16, 2015
Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin ActivationOliver Staeck, Torsten Slowinski, Ina Lieker, et al.
Pageof 8

Showing results (31-40 of 79) with videos related to

Sort By:
Pageof 8
Transplantation|April 2, 2014
Podocyte foot process effacement in postreperfusion allograft biopsiesGeorge W Burke, Jei-Wen Chang, Victoriano Pardo, et al.
American Journal of Physiology. Renal Physiology|November 24, 2017
Podocytes exhibit a specialized protein quality control employing derlin-2 in kidney diseaseGuohui Ren, Nicholas J Tardi, Fumihiko Matsuda, et al.
Transplantation|April 14, 2012
Podocyte foot process effacement in postreperfusion allograft biopsies correlates with early recurrence of proteinuria in focal segmental glomerulosclerosisJei-Wen Chang, Victoriano Pardo, Junichiro Sageshima, et al.
Cardio-Oncology (London, England)|January 15, 2024
Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory studyJian Chu, Lillian Tung, Issam Atallah, et al.
Cardio-Oncology (London, England)|February 6, 2024
Correction: Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin‑treated breast cancer patients: a prospective exploratory studyJian Chu, Lillian Tung, Issam Atallah, et al.
Journal of the American Society of Nephrology : JASN|June 8, 2019
Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney DiseaseSalim S Hayek, Douglas P Landsittel, Changli Wei, et al.
Annals of the New York Academy of Sciences|August 14, 2018
Wnt signaling in bone, kidney, intestine, and adipose tissue and interorgan interaction in agingDi Chen, Rong Xie, Bing Shu, et al.
Kidney International Reports|January 10, 2022
Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte β3 IntegrinMichelle A Hladunewich, Dan Cattran, Sanjeev M Sethi, et al.
Transplantation|July 12, 2013
Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapyNada Alachkar, Changli Wei, Lois J Arend, et al.
Transplantation|September 16, 2015
Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin ActivationOliver Staeck, Torsten Slowinski, Ina Lieker, et al.
Pageof 8